Antifungal activity of micafungin against clinical isolates of Candida and Aspergillus species second biennial surveillance report

• Kobayashi Intetsu

  Chemotherapy Division, Mitsubishi Chemical Medience Corp.

• Suzuki Makoto

  Chemotherapy Division, Mitsubishi Chemical Medience Corp.

• Saika Takeshi

  Chemotherapy Division, Mitsubishi Chemical Medience Corp.

• Ikeda Fumiaki

  Product Marketing, Astellas Pharma Inc.

• Hori Yasuhiro

  Product Marketing, Astellas Pharma Inc.

• Matsumoto Satoru

  Pharmacology Research Labs., Astellas Pharma Inc.

• Kawamura Ikuo

  Post Marketing Medical Research, Astellas Pharma Inc.

• Yoshiyasu Takashi

  Post Marketing Medical Research, Astellas Pharma Inc.

• Horita Hisanori

  Post Marketing Medical Research, Astellas Pharma Inc.

Bibliographic Information

Other Title

• 臨床分離Ｃａｎｄｉｄａ属およびＡｓｐｅｒｇｉｌｌｕｓ属真菌のｍｉｃａｆｕｎｇｉｎ感受性―第２報―
• Second biennial surveillance report

Abstract

In a postmarketing surveillance study for comparison with previous results, we determined the susceptibility to micafungin (MCFG) and other antifungal drugs-amphotericin B, fluconazole, itraconazole, miconazole, flucytosine, caspofungin, and voriconazole-for 690 strains (410 of 6 Candida species and 280 of 4 Aspergillus species), isolated from patients with suspected fungal infection visiting medical facilities in Japan between January 2005 and December 2006. MIC levels against Candida and Aspergillus species were determined according to the broth microdilution, as specified by Clinical and Laboratory Standards Institute (CLSI) documents M27-A and M38-P. For Candida species, MIC levels for score 2, currently being standardized by the CLSI as criteria for MIC determination of echinocandin antifungal drugs against Candida species, were determined for reference in addition to score O. MIC₉₀ levels of MCFG against 130 Candida albicans isolates, including those fluconazole-resistant were 0.015 μg/mL, and against 50 isolates each of Candida tropicalis 0.03 μg/mL, Candida glabrata 0.015 μg/mL, Candida parapsilosis 2 μg/mL, Candida krusei 025 μg/mL, and Candida guilliermondii 4 μg/mL. MIC₉₀ levels of MCFG against 100 Aspergillus fumigatus isolates were 0.015 μg/mL and against another 180 Aspergillus isolates 0.008 to 0.03 μg/mL. MIC levels of MCFG against Candida and Aspergillus species determined in this study remained unchanged compared to those against isolates sampled in 2001-2002 and 2003-2004. MIC levels of MCFG for score 2 tended to be lower than those for score O, with a markedly significant difference between scores observed in MIC against C. guilliermondii. These findings indicate that MCFG exerts the most potent antifungal activity of antifungal drugs studied and that the susceptibility of target fungi to MCFG remained high compared to previous biennial surveillance conducted from 2001.

Journal

• Japanese Journal of Chemotherapy

  Japanese Journal of Chemotherapy 56 (3), 344-352, 2008

  Japanese Society of Chemotherapy

Keywords

• Candida
• Aspergillus
• micafungin
• antifungal activity

Details

• CRID: 1390001206287287424
• NII Article ID: 130004298369
• NII Article ID: 10021192694
• NII Book ID: AN10472127
• DOI: 10.11250/chemotherapy1995.56.344
• ISSN: 18845886
• ISSN: 13407007
• Web Site: https://search.jamas.or.jp/link/ui/2008280201
• Text Lang: ja
• Data Source:
  • JaLC
  • CiNii Articles
• Abstract License Flag: Disallowed